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Research
Among women, the prevalence of diagnosed 
diabetes doubled from 1980 to 2010, with the 
age-adjusted prevalence increasing from 2.9% 
to 5.9% [Centers for Disease Control and 
Prevention (CDC) 2011a]. Although increased 
body mass index (BMI) is a major risk factor of 
diabetes (Colditz et al. 1995; Flegal et al. 2010; 
Mokdad et al. 2000), other factors are thought 
to be involved in the type 2 diabetes (T2DM) 
epidemic (Stahlhut et al. 2007; Svensson et al. 
2011; Thayer et al 2012). In particular, certain 
types of environmental endocrine-disrupting 
chemicals (EDCs) have been implicated as hav-
ing the ability to alter both adiposity and insu-
lin resistance (Hatch et al. 2008; Latini et al. 
2009; Newbold 2010; Stahlhut et al. 2007). 
Phthalates may be among those EDCs with 
the joint ability to impact adipogenesis and 
dysregulate glucose metabolism (Casals-Casas 
et al. 2008; Desvergne et al. 2009; Grun and 
Blumberg 2007).
Phthalates are a class of chemicals used 
in the manufacturing of a variety of products 
(Crinnion 2010; Hauser and Calafat 2005; 
Romero-Franco et al. 2011). These chemi-
cals are often used as plasticizers or solvents 
in food packaging, cosmetics, perfumes, nail 
polishes, flooring, and other industrial prod-
ucts. For the past 50 years, phthalate produc-
tion has increased (Baillie-Hamilton 2002). 
Phthalate exposure is nearly ubiquitous, with 
> 75% of the U.S. population having detect-
able urine concentrations of many phthalate 
metabolites (Hauser and Calafat 2005).
Recent studies have suggested that phtha-
lates may disrupt metabolism and adipo  genesis 
(Casals-Casas et al. 2008; Desvergne et al. 
2009; Grun and Blumberg 2007). Specifically, 
phthalates can bind to peroxisome proliferator-
activated receptors (PPAR) alpha and gamma, 
which regulate glucose metabolism and adipo-
genesis, respectively (Casals-Casas et al. 2008; 
Desvergne et al. 2009; Grun and Blumberg 
2007). Dysregulation of glucose metabolism, 
possibly through increased insulin resistance, is 
a hallmark of T2DM.
In a cross-sectional study of a represen-
tative sample of U.S. men participating in 
NHANES, Stahlhut et al. (2007) showed that 
exposure to higher levels of phthalates was 
associated with increased waist circumference 
and insulin resistance—both risk factors for 
T2DM. In a cross-sectional study of Mexican 
women, Svensson et al. (2011) found that 
higher exposure of certain phthalates was asso-
ciated with T2DM. Although the prevalence 
of diabetes is similar among men and women 
in the United States, differences in fat storage 
and hormonal profiles related to insulin resis-
tance exist (Tsatsoulis et al. 2009). If certain 
environmental chemicals have the ability to 
alter adiposity and insulin resistance, then 
exposure to these chemicals could vary by 
sex. Women may be particularly vulnerable 
to metabolic disruption of phthalates, given 
their higher concentrations of certain urinary 
phthalate metabolites (Silva et al. 2004).
In this study, we analyzed data from 
women 20–79 years of age who partici-
pated in the National Health and Nutrition 
Examination Survey 2001–2008 (NHANES). 
We estimated the association of diabetes 
with concentrations of mono  ethyl phthalate 
(MEP), mono-n-butyl phthalate (MnBP), 
mono-isobutyl phthalate (MiBP), mono  benzyl 
phthalate (MBzP), mono-(3-carboxy  propyl) 
phthalate (MCPP), and the sum of three 
di(2-ethylhexyl) phthalate (DEHP) metabo-
lites [mono-(2-ethyl  hexyl) phthalate (MEHP), 
mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(MEHHP), and mono-(2-ethyl-5-oxohexyl) 
Address correspondence to T. James-Todd, Brigham 
and Women’s Hospital and Harvard Medical School, 
1620 Tremont St., Division of Women’s Health, 3rd 
Floor, Boston, MA 02120 USA. Telephone: (617) 
525-8193. Fax: (617) 525-7746. E-mail: tjames-todd@
bics.bwh.harvard.edu
This research was funded by the American Diabetes 
Association Mentor–based Minority Postdoctoral 
Fellowship Award (7-09-MI-06) and the National 
Institute of Environmental Health Sciences (grant 
R0 1ES018872). 
The authors declare they have no actual or potential 
competing financial interests.
Received 8 November 2011; accepted 1 June 2012.
Urinary Phthalate Metabolite Concentrations and Diabetes among Women 
in the National Health and Nutrition Examination Survey (NHANES) 2001–2008
Tamarra James-Todd,1 Richard Stahlhut,2 John D. Meeker,3 Sheena-Gail Powell,1 Russ Hauser,4,5 Tianyi Huang,1 
and Janet Rich-Edwards1,4
1Division of Women’s Health, Department of Medicine, Connors Center for Women’s Health and Gender Biology, Brigham and Women’s 
Hospital and Harvard Medical School, Boston, Massachusetts, USA; 2Department of Obstetrics and Gynecology, University of Rochester 
School of Medicine and Dentistry, Rochester, New York, USA; 3Department of Environmental Health Sciences, University of Michigan 
School of Public Health, Ann Arbor, Michigan, USA; 4Department of Epidemiology, and 5Department of Environmental Health, Harvard 
School of Public Health, Boston, Massachusetts, USA
Ba c k g r o u n d: Previous studies have shown that women have higher urinary concentrations of 
  several phthalate metabolites than do men, possibly because of a higher use of personal care products. 
Few studies have evaluated the association between phthalate metabolites, diabetes, and diabetes-
related risk factors among women.
oB j e c t i v e: We explored the association between urinary phthalate metabolite concentrations and 
diabetes among women who participated in a cross-sectional study.
Me t h o d s : We used urinary concentrations of phthalate metabolites, analyzed by the Centers 
for Disease Control and Prevention, and self-reported diabetes of 2,350 women between 20 and 
79 years of age who participated in the NHANES (2001–2008). We used multiple logistic 
regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and adjusted for urinary 
creatinine, sociodemographic characteristics, dietary factors, and body size. A secondary analysis was 
conducted for women who did not have diabetes to evaluate the association between phthalate 
metabolite concentrations and fasting blood glucose (FBG), homeostasis model assessment–
estimated insulin resistance, and glycosylated hemoglobin A1c.
re s u l t s: After adjusting for potential confounders, women with higher levels of mono-n-butyl 
phthalate (MnBP), mono-isobutyl phthalate (MiBP), mono  benzyl phthalate (MBzP), mono-(3-
carboxy  propyl) phthalate (MCPP), and three di-(2-ethylhexyl) phthalate metabolites (∑DEHP) 
had an increased odds of diabetes compared with women with the lowest levels of these phtha-
lates. Women in the highest quartile for MBzP and MiBP had almost twice the odds of diabetes 
[OR = 1.96 (95% CI: 1.11, 3.47) and OR = 1.95 (95% CI: 0.99, 3.85), respectively] compared 
with women in the lowest quartile. Nonmonotonic, positive associations were found for MnBP and 
∑DEHP, whereas MCPP appeared to have a threshold effect. Certain phthalate metabolites were 
positively associated with FBG and insulin resistance.
discussion: Urinary levels of several phthalates were associated with prevalent diabetes. Future 
prospective studies are needed to further explore these associations to determine whether phthalate 
exposure can alter glucose metabolism and increase the risk of insulin resistance and diabetes.
key w o r d s : diabetes, di(2-ethylhexyl) phthalate, mono  benzyl phthalate, mono-(3-carboxypropyl) 
phthalate, mono  ethyl phthalate, mono-isobutyl phthalate, mono-n-butyl phthalate, women. Environ 
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phthalate (MEOHP)]. To estimate the asso-
ciation between these phthalates and diabetes, 
we adjusted for socio  demographic charac-
teristics and behavioral factors. Because diet 
is one of the main sources of exposure for cer-
tain phthalates, we adjusted for dietary factors, 
including total caloric and fat intake (Grun 
and Blumberg 2007; Hauser and Calafat 
2005). We also adjusted for BMI and waist 
circum  ference, which could not be ruled out 
as potential intermediates or con  founders 
given the cross-sectional study design. To 
determine whether phthalate exposure was 
associated with factors that likely precede the 
onset of diabetes, we conducted a second-
ary analysis to estimate associations between 
phthalate metabolites and fasting blood glu-
cose (FBG), homeo  stasis model assessment–
estimated insulin resistance (HOMA-IR), and 
gly  cosylated hemo  globin A1c (A1c) among 
women who did not have a diagnosis of dia-
betes. We hypothesized that higher urinary 
phthalate levels would be associated with an 
increased odds of   prevalent diabetes.
Methods
Study population. NHANES is a survey of a 
nationally representative sample of the non-
institutionalized U.S. civilian population con-
ducted by the CDC’s National Center for 
Health Statistics. NHANES uses a complex, 
multi-staged, stratified, clustered design; over-
sampling is conducted to ensure that certain 
subgroups are well represented, such as blacks, 
Mexican-Americans, and people with low 
incomes. Each year between 2001 and 2008, 
NHANES enrolled approximately 5,000 men 
and women. Data were collected on demo-
graphic, dietary, and behavioral factors using 
in-home questionnaires. Anthropometric 
information was collected through physi-
cal examinations conducted in mobile exam 
units. Written informed consent was obtained 
from all NHANES participants. Data on the 
NHANES web site are de-identified and pub-
lically accessible. Additional details on study 
procedures, data documentation, and question-
naires are available elsewhere (CDC 2011b).
Phthalate metabolite measurements. 
Phthalate metabolites were measured in a ran-
dom, one-third subsample of NHANES partic-
ipants with urine measurements. Urine samples 
were collected and frozen at –20°C. These 
samples were shipped to the CDC’s National 
Center for Environmental Health (Atlanta, 
GA) for analysis. Phthalate metabolites, rather 
than their parent compounds, were analyzed 
to reduce potential exposure misclassification 
(Latini 2005). The metabolites were measured 
using solid-phase extraction, high performance 
liquid chromatography, and tandem mass spec-
trometry. These methods have been described 
in detail elsewhere (CDC 2011c; Hauser and 
Calafat 2005; Silva et al. 2004).
The phthalates measured between 2001 and 
2008 varied by year. We selected phthalates 
that were measured in all years with > 60% of 
sample concentrations above the limit of detec-
tion (LOD). Based on these criteria, we exam-
ined MEP, MnBP, MiBP, MBzP, and MCPP. 
Because of the high correlation between DEHP 
metabolites, we calculated the molar sum of 
the DEHP metabolites—MEHP, MEHHP, 
and MEOHP (∑DEHP). Exposures to indi-
vidual phthalate metabolites and ∑DEHP were 
classified according to quartiles based on the 
overall population phthalate levels, with the 
lowest quartile used as the referent category. 
For each phthalate, we evaluated outliers by 
their sampling weight (CDC 2011d; Thayer 
et al. 2012) and excluded those values that 
were substantially outside of range (> 99th per-
centile). Measured concentrations below the 
LOD were replaced with the LOD divided by 
the square root of two.
Diabetes. Participants who responded “yes” 
to the question “Other than during pregnancy, 
have you ever been told by a doctor or health 
professional that you have diabetes or sugar dia-
betes?” were classified as persons with diabetes. 
If respondents refused to answer the question, 
did not know the answer, or had a missing 
value, we excluded them from the analysis.
FBG, HOMA-IR, and A1c. FBG and fast-
ing insulin levels were available for a subset 
of women who were randomly assigned to a 
morning fast, whereas A1c was available for the 
full sample. We calculated HOMA-IR as an 
indicator of insulin resistance: [blood glucose 
(millimoles per liter) × insulin levels (micro-
units per milliliter)/22.5].
Covariates. We considered the age, race/
ethnicity, highest level of education, poverty 
status, fasting time, total caloric, and total fat 
intake of the participants as potential con-
founders. We also evaluated BMI and waist 
circumference as potential intermediates.
The age of the respondents was catego-
rized as 20–29, 30–39, 40–49, 50–59, 60–69, 
or 70–79 years. We restricted our upper age 
limit to < 80 years, because participants ≥ 80 
years of age were assigned an age of 80 or 85 
in some surveys to protect confidentiality. 
Race/ethnicity was categorized as Mexican-
American, black, white (reference), and other 
(including “other Hispanic” and mixed race). 
We categorized education as high school grad-
uate or less (reference), some college, college 
graduate or higher. Poverty status was clas-
sified as poverty income ratio < 1 versus ≥ 1 
(reference) based on the federal-based poverty 
threshold and household income information 
(Ali et al. 2011). Fasting time was modeled 
as a continuous variable. Physical activity was 
cate  gorized as any self-reported vigorous or 
moderate physical recreation activity versus 
none (reference), and smoking status was cate-
gorized as current, past, or never (reference).
Total caloric intake and total fat intake 
were taken from the summary results of the 
24-hr dietary history. From 2001 to 2002, 
dietary food records were collected for one 
day. From 2003 to 2008, a second day was 
also assessed, in which case we used the mean 
of the two values. We evaluated these vari-
ables in quartiles, with the lowest quartile as 
the reference group.
BMI was categorized as underweight 
(< 18.5 kg/m2), normal weight [18.5–24 kg/m2 
(reference)], overweight (25–29 kg/m2), and 
obese (≥ 30 kg/m2). Waist circumference was 
dichotomized at the median [< 94.5 cm (refer-
ence) vs. ≥ 94.5 cm].
Statistical analysis. When evaluating 
the association between urinary phthalate 
metabolites and diabetes, our primary analy-
sis took into account the complex sampling 
scheme of NHANES. We performed multi-
variable logistic regression using PROC 
SURVEYLOGISTIC. We constructed four 
separate models to estimate the association 
between each phthalate metabolite and dia-
betes. All models were adjusted for urinary 
creatinine as a covariate; this adjustment is 
an alternative to using creatinine-corrected 
phthalate levels (Barr et al. 2005). We consid-
ered a variable a confounder if its inclusion in 
the model changed the beta coefficient for any 
of the phthalate exposure quartiles by > 10%. 
We evaluated four main models: Model 1 rep-
resented our crude model, which adjusted for 
urinary creatinine only; model 2 adjusted for 
urine creatinine plus fasting time and socio-
demographic factors (age, race/ethnicity, edu-
cation, poverty status); model 3 adjusted for 
model 2 variables plus behavioral factors. For 
MnBP, MEP, and MBzP, behavioral fac-
tors included physical activity, smoking sta-
tus, total caloric intake, total fat intake. For 
MCPP and MiBP, behavioral factors included 
only total caloric and fat intake, whereas for 
∑DEHP these factors included total caloric 
and fat intake, as well as physical activity. 
Model 4 adjusted for model 3 variables, and 
included BMI and waist circumference. For 
the MiBP, MCPP, and ∑DEHP models, we 
did not include physical activity or smoking 
status, as these variables did not alter the beta 
for these phthalates by > 10%. We evalu-
ated the association between urine creatinine 
(categorized into quartiles) and diabetes using 
logistic regression; we did not find urine 
creatinine to be significantly associated with 
diabetes in this analysis. Odds ratios (ORs) 
and 95% confidence intervals (CIs) were cal-
culated to estimate the association between 
each phthalate and diabetes using appropriate 
sample weights, strata, and cluster variables 
for this subgroup analysis (CDC 2011e).
We conducted a secondary analysis for 
those women who did not self-report diabe-
tes in our study population. Given the highly Urinary phthalate levels and diabetes in women
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skewed distribution of FBG, HOMA-IR, and 
A1c values, even after log transformation, we 
used median regression to explore the asso-
ciation between phthalates and the three out-
comes of interest (Burgette et al. 2011; SAS 
Institute Inc. 2011). We log-transformed 
HOMA-IR (Bonora et al. 2000; Emoto et al. 
1999; Hermans et al. 1999). Exact 95% CIs 
were generated by bootstrap resampling with 
5,000 repeats. For the secondary analysis 
that evaluated the association between uri-
nary phthalate concentrations and FBG and 
HOMA-IR, we did not use sample weights, 
strata, or cluster variables, because this analy-
sis was based on two somewhat overlapping 
subsets of the overall NHANES (2001–2008) 
study population (i.e., participants randomly 
selected for the urinary phthalate laboratory 
analysis and those randomly selected for a 
morning fasting blood draw). To maintain 
consistency with respect to model selection, 
we used models without sample weights, strata 
or cluster variables for the analysis of phthalate 
metabolite concentrations and hemoglobin 
A1c, as well. We adjusted for variables used 
in the creation of weights in our final models 
(Korn and Graubard 1991). All analyses were 
conducted using SAS software (version 9.2; 
SAS Institute Inc., Cary, NC).
Results
Descriptive statistics. A total of 3,064 women 
between 20 and 79 years of age had available 
data on both diabetes and phthalates. For the 
present analysis, we excluded women who 
were pregnant (n = 294), had kidney problems 
(n = 62), or both (n = 2), and women with 
missing covariates included in our models 
(n = 356); a total of 2,350 women were 
included in our primary analysis. Because 
women with outlier information on phthalates 
were excluded, total n varied slightly for each 
phthalate metabolite (21–25 additional women 
were excluded). Analyses of associations with 
FBG, HOMA-IR, and A1c values included 
985, 971, and 2,092 women, respectively. 
An additional 6–18 women were excluded 
from the secondary analysis due to outlying 
phthalate information.
Table 1 summarizes the weighted geo-
metric means (with 95% CI) of each phthalate 
Table 1. Study population characteristics of women 20–79 years of age (NHANES 2001–2008).
Characteristic n (%) MEP MnBP MiBP MBzP MCPP ∑DEHP (× 100)
Total 2,350 (100) 164.8 (150.5, 180.3) 17.7 (16.6, 18.9) 3.7 (3.5, 3.9) 9.7 (9.0, 10.6) 2.0 (1.8, 2.1) 11.1 (10.3, 12.0)
Age (years)
20–29 429 (18.3) 190.0 (161.3, 223.8) 23.9 (20.9, 27.3) 5.0 (4.4, 5.7) 16.4 (14.3, 18.9) 2.7 (2.3, 3.0) 16.6 (14.5, 19.0)
30–39 417 (17.7) 185.7 (156.5, 220.3) 19.0 (16.5, 21.8) 4.3 (3.7, 4.9) 11.9 (10.1, 13.9) 2.1 (1.8, 2.4) 12.9 (11.1, 14.9)
40–49 483 (20.6) 199.7 (176.1, 226.5) 16.9 (14.7, 19.6) 3.7 (3.3, 4.3) 9.5 (8.2, 11.1) 1.9 (1.7, 2.1) 10.2 (8.9, 11.7)
50–59 358 (15.2) 129.6 (106.7, 157.4) 16.2 (14.1, 18.7) 3.2 (2.8, 3.7) 7.4 (6.2, 8.9) 1.8 (1.6, 2.1) 9.6 (8.3, 11.2)
60–69 394 (16.8) 127.9 (102.9, 159.1) 13.4 (11.2, 16.2) 2.7 (2.2, 3.2) 5.9 (4.8, 7.2) 1.5 (1.3, 1.8) 8.5 (7.4, 9.8)
70–79 269 (11.5) 125.7 (105.6, 149.6) 15.6 (13.3, 18.3) 2.5 (2.2, 3.0) 7.3 (6.1, 8.7) 1.6 (1.4, 1.9) 8.1 (6.9, 9.5)
Race/ethnicity
Mexican-American 469 (20.0) 248.9 (213.5, 290.2) 21.2 (18.3, 24.5) 5.3 (4.6, 6.1) 10.4 (8.6, 12.7) 2.1 (1.8, 2.5) 11.2 (9.8, 12.9)
White 1,142 (48.6) 142.0 (128.0, 157.6) 16.0 (14.8, 17.2) 3.1 (2.9, 3.4) 8.9 (8.1, 9.9) 1.9 (1.7, 2.0) 10.2 (9.3, 11.2)
Black 510 (21.7) 334.3 (293.3, 381.0) 27.6 (24.8, 30.8) 6.8 (6.1, 7.6) 14.8 (12.6, 17.4) 2.2 (2.0, 2.4) 17.3 (15.6, 19.1)
Other 229 (9.7) 159.1 (127.1, 199.2) 20.1 (16.5, 24.5) 4.9 (4.1, 5.8) 10.5 (7.9, 13.9) 2.1 (1.7, 2.6) 12.3 (9.9, 15.2)
Education
≤ High school 1,146 (48.8) 188.1 (165.7, 213.4) 18.7 (17.1, 20.4) 3.8 (3.5, 4.2) 10.6 (9.7, 11.7) 2.0 (1.9, 2.2) 11.2 (10.1, 12.5)
Some college 736 (31.3) 176.9 (154.8, 202.1) 18.1 (15.9, 20.7) 3.7 (3.3, 4.2) 10.8 (9.3, 12.5) 2.0 (1.8, 2.3) 11.3 (9.9, 12.9)
≥ College graduate 468 (19.9) 120.9 (103.0, 142.0) 15.8 (14.1, 17.8) 3.4 (2.9, 3.9) 7.3 (6.3, 8.6) 1.8 (1.6, 2.1) 10.7 (9.4, 12.2)
Family poverty to income ratio
Above poverty (≥ 1) 1,887 (80.3) 157.7 (143.6, 173.2) 16.8 (15.7, 18.1) 3.5 (3.2, 3.7) 9.0 (8.2, 9.8) 1.9 (1.8, 2.0) 10.8 (10.0, 11.7)
Below poverty (< 1) 463 (19.7) 215.1 (180.3, 256.5) 24.1 (20.5, 28.5) 5.1 (4.4, 6.0) 16.0 (13.4, 19.1) 2.4 (2.1, 2.8) 13.0 (10.7, 15.7)
Smoking status
Never smoker 1,393 (59.3) 159.9 (144.6, 176.9) 16.9 (15.6, 18.4) 3.7 (3.4, 4.0) 9.6 (8.8, 10.5) 2.0 (1.8, 2.1) 11.5 (10.3, 12.8)
Current smoker 490 (20.9) 171.7 (148.4, 198.7) 21.5 (18.8, 24.5) 3.8 (3.3, 4.4) 11.7 (10.1, 13.4) 2.0 (1.8, 2.3) 11.3 (9.9, 13.0)
Past smoker 467 (19.9) 170.4 (143.9, 201.8) 16.3 (14.5, 18.3) 3.5 (3.0, 4.1) 8.3 (6.9, 10.0) 1.9 (1.7, 2.2) 9.9 (8.7, 11.4)
Moderate or vigorous physical activity
Yes 1,343 (57.2) 154.9 (139.6, 171.9) 17.0 (15.7, 18.3) 3.5 (3.2, 3.7) 9.5 (8.5, 10.6) 2.0 (1.8, 2.1) 11.1 (10.3, 12.0)
No 1,007 (42.9) 184.8 (159.4, 214.1) 19.3 (17.2, 21.6) 4.1 (3.6, 4.6) 10.2 (9.0, 11.4) 2.0 (1.8, 2.1) 11.1 (9.8, 12.6)
Total calories (kcal)
< 1,464 830 (35.3) 174.7 (154.0, 198.2) 18.9 (17.0, 20.9) 3.8 (3.4, 4.3) 10.1 (8.9, 11.4) 2.0 (1.8, 2.2) 10.4 (9.4, 11.5)
1,464 to < 1,942 700 (29.8) 165.5 (142.9, 191.7) 16.5 (14.7, 18.5) 3.4 (3.0, 3.8) 8.8 (7.8, 9.9) 1.8 (1.6, 2.0) 10.8 (9.6, 12.2)
1,942 to < 2,550 542 (23.1) 144.4 (124.8, 167.1) 16.1 (14.4, 18.0) 3.5 (3.1, 4.0) 9.2 (7.9, 10.8) 1.8 (1.7, 2.1) 11.0 (9.6, 12.5)
≥ 2,550 278 (11.8) 183.7 (149.6, 225.7) 22.0 (18.4, 26.4) 4.5 (3.7, 5.4) 12.7 (10.4, 15.7) 2.6 (2.2, 3.2) 14.6 (12.1, 17.6)
Total fat (g)
< 49.3 756 (32.2) 172.6 (149.9, 198.8) 18.5 (16.4, 20.8) 3.9 (3.5, 4.3) 9.6 (8.5, 10.9) 1.9 (1.7, 2.1) 10.2 (9.2, 11.4)
49.3 to < 70.6 679 (28.9) 147.9 (126.0, 173.7) 15.9 (14.0, 18.1) 3.4 (3.0, 3.8) 8.7 (7.5, 10.2) 1.9 (1.7, 2.1) 10.1 (8.9, 11.4)
70.6 to < 97.5 561 (23.9) 163.8 (144.2, 186.0) 17.2 (15.7, 18.9) 3.5 (3.2, 3.9) 9.7 (8.5, 11.2) 1.9 (1.7, 2.2) 12.1 (10.7, 13.7)
≥ 97.5 354 (15.1) 185.8 (151.2, 228.4) 21.2 (18.0, 24.9) 4.2 (3.6, 4.9) 12.1 (9.9, 14.7) 2.4 (2.1, 2.8) 13.5 (11.8, 15.4)
BMI (kg/m2)
Underweight (< 18.5) 48 (2.0) 112.3 (72.3, 174.3) 14.9 (10.2, 21.9) 2.9 (2.0, 4.3) 7.1 (5.1, 9.9) 1.6 (1.1, 2.2) 9.9 (7.2, 13.6)
Normal (18.5 to < 24) 702 (29.9) 134.9 (115.6, 157.4) 15.0 (13.4, 16.9) 3.1 (2.8, 3.4) 7.6 (6.5, 8.8) 1.7 (1.5, 1.9) 9.1 (8.1, 10.3) 
Overweight (25 to < 30) 707 (30.1) 171.4 (149.6, 196.4) 18.7 (17.0, 20.5) 3.8 (3.4, 4.2) 10.1 (8.9, 11.4) 2.1 (1.9, 2.3) 11.3 (10.1, 12.6)
Obese (≥ 30) 893 (38.0) 202.3 (177.9, 230.0) 20.5 (18.7, 22.3) 4.4 (4.0, 4.9) 12.6 (11.4, 13.9) 2.2 (2.1, 2.4) 13.6 (12.5, 14.9)
Waist circumference (cm)
< 94.5 1,194 (50.8) 151.7 (135.7, 169.7) 16.4 (15.1, 17.8) 3.4 (3.1, 3.7) 8.7 (7.8, 9.8) 1.8 (1.7, 2.0) 10.2 (9.2, 11.3)
≥ 94.5 1,156 (49.2) 182.9 (164.0, 204.0) 19.6 (17.9, 21.4) 4.1 (3.7, 4.5) 11.2 (10.1, 12.3) 2.1 (2.0, 2.3) 12.4 (11.3, 13.6)
Diabetes status
Yes 215 (9.2) 188.2 (138.0, 256.6) 20.1 (17.1, 23.7) 4.5 (3.7, 5.5) 11.5 (9.5, 14.0) 2.2 (1.8, 2.7) 12.6 (10.6, 15.0)
No 2,135 (90.9) 163.3 (149.0, 178.9) 17.6 (16.4, 18.8) 3.6 (3.4, 3.9) 9.6 (8.8, 10.5) 1.9 (1.8, 2.1) 11.0 (10.2, 11.9)
Values are geometric mean (95% CI).James-Todd et al.
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for the study population. Approximately 
9% of women reported that a physician had 
diagnosed them with diabetes (n = 217). As 
expected, women with diabetes were signifi-
cantly more likely to have a higher BMI and 
waist circumference, and to be older, non-
white, and to have lower physical activity (all 
p < 0.05) (data not shown).
Association between phthalates and 
diabetes. In Table 2, we present estimated 
associations between phthalate metabolites 
and diabetes. Statistically significant crude 
associations (model 1) were evident between 
MnBP, MiBP, MBzP, and ∑DEHP with dia-
betes prevalence. Although some associations 
appeared to have a non  monotonic, increasing 
odds of diabetes, others seemed to suggest a 
threshold for an increasing odds of diabetes. 
Only MiBP appeared to have a monotonically 
increasing association with diabetes across 
quartiles for the crude associations, with the 
fourth quartile of MiBP conferring a 1.85 
increased odds of diabetes (95% CI: 1.04, 
3.27). On the other hand, there was evidence 
of a threshold for MBzP and MCPP, in which 
greater than median levels of these phtha-
lates were associated with an increased odds 
of prevalent diabetes. MnBP and ∑DEHP 
had non  monotonic associations with preva-
lent diabetes. In fact, the strongest association 
for these phthalates appeared to be the third 
exposure quartile. No apparent association 
existed between MEP and diabetes.
Adjustments made in models 2 and 3 only 
slightly altered associations between all phtha-
lates and prevalent diabetes. Having higher 
than median (i.e., third or fourth quartile lev-
els of exposure) for MBzP and MCPP contin-
ued to confer an increased odds of diabetes. 
Women in the third quartile (Q3) and in 
the fourth quartile (Q4) of MBzP had 1.80 
and 1.96 times the odds of prevalent diabe-
tes, respectively (95% CI for Q3: 1.16, 2.81; 
95% CI for Q4: 1.11, 3.47). Likewise, 
women in Q3 and Q4 for MCPP had a 1.55 
and 1.68 increased odds of diabetes, respec-
tively (95%  I for Q3: 0.98, 2.44; 95% CI for 
Q4: 1.03, 2.75). MnBP and ∑DEHP con-
tinued to have non  monotonic associations 
with Q3 showing a higher odds of diabetes 
(OR for Q3 = 1.71; 95% CI: 1.04, 2.81 and 
OR for Q3 = 1.73; 1.03, 2.91, respectively). 
The monotonically increasing association seen 
for MiBP remained, with increasing levels 
of MiBP conferring an increased odds of   
diabetes. However, this association had 
border  line statistical significance. Additional 
adjustment for BMI and waist circumference 
did little to the alter these associations.
Association between phthalates, FBG, 
HOMA-IR, and hemoglobin A1c. In Table 3, 
we present the association between phthalates 
and biomarkers of diabetes risk. We found 
consistent associations between MBzP and 
MiBP and FBG, after adjustment for socio-
demographic, behavioral, and dietary factors 
(model 1). For MBzP, we found an inverse 
association with FBG, with the median blood 
glucose level in the highest quartile being 
2.27 mg/dL lower than the median FBG for 
participants in the lowest quartile (95% CI: 
–4.76, 0.21). However, this association did 
not reach statistical significance. On the other 
hand, MiBP showed an increasing monotonic 
association with FBG. Women with the high-
est quartile of MiBP had a 5.86 mg/dL higher 
median FBG compared with women in the 
lowest quartile (95% CI: 3.55, 8.17). These 
patterns held even after adjusting for BMI 
and waist circumference. No apparent pat-
terns were present for other urinary phthalate 
metabolites and FBG.
After adjusting for sociodemographic, 
behavioral, and dietary factors, we found an 
association between certain phthalate metabo-
lites and HOMA-IR. Women with higher 
MiBP levels had higher median ln-HOMA-IR 
levels. This association was not linear, but the 
highest quartile conferred a higher median 
ln-HOMA-IR level compared with partici-
pants in the lowest quartile of MiBP (adjusted 
β for ln-HOMA-IR = 0.22; 95% CI: 0.06, 
0.38). Likewise, DEHP had a non  monotonic 
positive association with ln-HOMA-IR, 
with the highest quartile of MiBP conferring 
higher ln-HOMA-IR levels (adjusted β for 
ln-HOMA-IR = 0.19; 95% CI: 0.02, 0.35). 
Associations between other urinary phtha-
late metabolites and ln-HOMA-IR were not 
present. Furthermore, associations between 
urinary phthalate metabolites and hemoglo-
bin A1c did not appear among this subset of 
women without diabetes. These associations 
were similar with further adjustment of BMI 
and waist circumference (model 2).
Discussion
Women with higher urine levels of MnBP, 
MiBP, MBzP, MCPP, and ∑DEHP were 
more likely to have reported diabetes than 
were women with the lowest levels, even after 
accounting for sociodemographic, behavioral, 
and dietary factors. The addition of BMI 
attenuated some associations, whereas others 
became stronger. Non  monotonic associations 
were seen for MnBP and ∑DEHP, with the 
greatest increased odds being seen among 
women in Q3. Although evidence of a 
threshold effect appeared to be present for 
MBzP and MCPP, increasing levels of MiBP 
Table 2. Association [OR (95% CI)] between urinary phthalate metabolites and diabetes among women 
20–79 years of age (NHANES 2001–2008).
Urinary phthalate metabolite Model 1a Model 2b Model 3c Model 4d
MEP
Q1
Q2 1.04 (0.65–1.68) 1.00 (0.63–1.59) 0.95 (0.60–1.51) 0.93 (0.58–1.49)
Q3 1.08 (0.62–1.88) 1.17 (0.64–2.13) 1.09 (0.61–1.96) 1.19 (0.65–2.20)
Q4 1.10 (0.58–2.06) 0.94 (0.49–1.80) 0.89 (0.47–1.67) 0.89 (0.48–1.68)
MnBP
Q1
Q2 1.37 (0.84–2.24) 1.32 (0.80–2.18) 1.29 (0.78–2.13) 1.31 (0.78–2.22)
Q3 2.01 (1.21–3.36) 1.76 (1.05–2.94) 1.71 (1.04–2.81) 1.73 (1.01–2.96)
Q4 1.32 (0.76–2.28) 1.06 (0.59–1.89) 1.06 (0.61–1.85) 1.14 (0.63–2.04)
MiBP
Q1
Q2 1.04 (0.66–1.66) 1.06 (0.67–1.68) 1.04 (0.66–1.67) 1.03 (0.64–1.67)
Q3 1.47 (0.85–2.53) 1.65 (0.91–2.98) 1.69 (0.93–3.06) 1.71 (0.92–3.16)
Q4 1.85 (1.04–3.27) 1.97 (0.99–3.93) 1.95 (0.99–3.85) 1.80 (0.89–3.65)
MBzP
Q1
Q2 0.81 (0.43–1.51) 0.85 (0.45–1.60) 0.78 (0.41–1.49) 0.84 (0.44–1.60)
Q3 1.73 (1.12–2.66) 1.84 (1.18–2.88) 1.80 (1.16–2.81) 1.90 (1.18–3.08)
Q4 1.60 (0.86–2.97) 1.95 (1.09–3.48) 1.96 (1.11–3.47) 1.99 (1.14–3.49)
MCPPe
Q1
Q2 0.78 (0.46–1.33) 0.85 (0.50–1.44) 0.83 (0.49–1.43) 0.76 (0.44–1.33)
Q3 1.46 (0.95–2.25) 1.54 (0.98–2.42) 1.55 (0.98–2.44) 1.47 (0.90–2.41)
Q4 1.45 (0.84–2.49) 1.62 (0.97–2.71) 1.68 (1.03–2.75) 1.64 (0.96–2.79)
∑DEHP (MEHP, MEHHP, and MEOHP)f
Q1
Q2 1.53 (0.92–2.54) 1.58 (0.97–2.57) 1.53 (0.95–2.48) 1.47 (0.90–2.40)
Q3 1.81 (1.10–2.99) 1.85 (1.13–3.02) 1.73 (1.03–2.91) 1.70 (0.96–3.03)
Q4 1.45 (0.84–2.51) 1.66 (0.90–3.05) 1.53 (0.82–2.87) 1.43 (0.75–2.75)
Q, quartile. For each of the metabolites, Q1 is the reference. 
aAdjusted for urine creatinine. bAdjusted for urine creatinine, age, race/ethnicity, education, poverty status, and fasting 
time. cAdjusted for urine creatinine, age, race/ethnicity, education, poverty status, fasting time, total caloric intake, total 
fat intake, smoking status, and physical activity. dAdjusted for urine creatinine, age, race/ethnicity, education, poverty 
status, fasting time, total caloric intake, total fat intake, smoking status, physical activity, BMI, and waist circumference. 
eSmoking and physical activity were not included in this analysis. fSmoking was not included in this analysis.Urinary phthalate levels and diabetes in women
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were associated with an increasing odds of 
diabetes. The strongest associations were seen 
among women with high levels of MiBP and 
MBzP, who had almost twice the odds of 
prevalent diabetes as women with the lowest 
level of exposure. Among women without 
self-reported diabetes, MiBP was positively 
associated with FBG, and MiBP and ∑DEHP 
were positively associated with HOMA-IR. No 
associations were present for urinary phthalate 
metabolites and hemoglobin A1c levels.
Our findings for phthalate metabolites 
and prevalent diabetes are similar to Svensson 
et al. (2011) who reported that higher levels 
of the ∑DEHP metabolites MEHHP and 
MEOHP were associated with diabetes 
in a study of 221 Mexican women. In the 
present study, ∑DEHP was associated with 
insulin resistance among women who did not 
report a diagnosis of diabetes. Because insulin 
resistance often precedes T2DM, this finding 
suggests that DEHP might affect T2DM risk 
via effects on insulin resistance. In addition, 
we found other phthalate metabolites to be 
associated with an increased odds of diabetes, 
as well as FBG levels and insulin resistance. 
These findings suggest that other phthalates 
might affect T2DM risk either through 
glucose dysregulation or insulin resistance.
Phthalates could potentially impact dia-
betes risk in a number of ways. By binding to 
PPAR gamma, it has been posited that phtha-
lates can up-regulate adipogenic genes leading 
to increased obesity in an environment where 
there is caloric excess (Grun and Blumberg 
2007; Hurst and Waxman 2003). Grun and 
Blumberg postulate that coupling the up- 
regulation of adipocyte production with caloric 
excess could lead to metabolically inactive fat 
tissue (Grun and Blumberg 2007). This in 
turn could lead to insulin resistance along with 
meta  bolic dysregulation and an increased risk of 
diabetes (Grun and Blumberg 2007). Another 
potential pathway in which this could occur 
is the ability of phthalates to bind to PPAR 
alpha (Casals-Casas et al. 2008; Desvergne et al. 
2009; Feige et al. 2010; Hurst and Waxman 
2003; Lapinskas et al. 2005), which modifies 
lipid handling to control circulating glucose 
levels (Desvergne et al. 2009; Tsatsoulis et al. 
2009). Although this pathway is less under-
stood (Desvergne et al. 2009), if certain types 
of phthalates dysregulate glucose metabolism by 
impacting lipid handling, then these phthalates 
could impact diabetes risk by altering beta-cell 
insulin secretion (Tordjman et al. 2002).
A previous study positing metabolic effects 
of high phthalate metabolite concentrations 
found associations between phthalate metabo-
lites and a measure of insulin resistance in male 
NHANES participants (Stahlhut et al. 2007). 
Animal and cellular models provide support for 
causal effects of phthalate exposures on diabetes 
risk. For example, rats given DEHP had altered 
insulin and glycogen levels, as well as increased 
blood glucose (Gayathri et al. 2004). In vitro 
models using liver cells have also found DEHP 
to reduce insulin receptor concentrations and 
glucose oxidation, suggesting that phthalates 
may lead to insulin resistance (Rengarajan et al. 
2007). These previous findings could provide 
useful information about the present study’s 
findings of an association between higher levels 
of ∑DEHP and ln-HOMA-IR.
Other phthalates associated with dia-
betes did not appear to be associated with 
insulin resistance or FBG among women 
without diagnosed diabetes. In fact, MnBP 
was not significantly associated with FBG, 
HOMA-IR, or A1c. MBzP and MCPP were 
inversely associated with FBG and A1c, 
respectively, after controlling for BMI and 
waist circumference. These conflicting results 
could be due to residual confounding or to an 
artifact of the cross-sectional study design.
The present exploratory research study had 
a number of limitations. As a cross-sectional 
Table 3. Association [difference in median value (95% CI)] between urinary phthalate metabolites and FBG, ln-HOMA-IR, and A1c among women 20–79 years of 
age without self-reported diabetes (NHANES 2001–2008).a
FBG (mg/dL) ln(HOMA-IR) A1c (%)
Phthalates Model 1b Model 2c Model 1b Model 2c Model 1b Model 2c
MEP n = 979 n = 965 n = 2,074
Q1
Q2 0.95 (–0.94, 2.85) 1.10 (–0.83, 3.04) 0.06 (–0.10, 0.23) 0.03 (–0.09, 0.14) 0.01 (–0.04, 0.06) –0.02 (–0.07, 0.02)
Q3 1.18 (–0.91, 3.27) 0.38 (–1.91, 2.67) 0.07 (–0.08, 0.23) 0.01 (–0.11, 0.14) –0.02 (–0.07, 0.03) –0.03 (–0.07, 0.02)
Q4 –0.03 (–2.16, 2.09) –0.61 (–2.99, 1.78) 0.10 (–0.07, 0.26) –0.04 (–0.17, 0.09) –0.03 (–0.08, 0.02) –0.05 (–0.10, 0.00)
MnBP n = 985 n = 971 n = 2,092
Q1 REF REF REF REF REF REF
Q2 –0.35 (–2.07, 1.38) –0.62 (–2.62, 1.38) 0.09 (–0.06, 0.25) 0.04 (–0.08, 0.16) 0.01 (–0.04, 0.06) 0.00 (–0.04, 0.04)
Q3 –0.19 (–2.22, 1.83) 0.19 (–2.05, 2.43) 0.09 (–0.06, 0.24) 0.11 (–0.01, 0.23) –0.02 (–0.08, 0.03) –0.03 (–0.08, 0.02)
Q4 –0.03 (–2.35, 2.30) –0.05 (–2.47, 2.36) 0.14 (–0.04, 0.31) 0.10 (–0.04, 0.24) –0.03 (–0.09, 0.02) –0.02 (–0.07, 0.03)
MBzP n = 985 n = 971 n = 2,092
Q1
Q2 0.00 (–1.70, 1.70) 0.77 (–1.11, 2.64) 0.09 (–0.07, 0.25) –0.01 (–0.12, 0.11) 0.01 (–0.04, 0.06) –0.01 (–0.05, 0.04)
Q3 –1.13 (–3.24, 0.98) –1.08 (–3.34, 1.18) 0.13 (–0.02, 0.28) 0.06 (–0.07, 0.19) 0.00 (–0.05, 0.05) –0.03 (–0.08, 0.01)
Q4 –2.27 (–4.76, 0.21) –2.80 (–5.32, –0.28) 0.10 (–0.09, 0.29) –0.07 (–0.22, 0.09) –0.03 (–0.09, 0.03) –0.03 (–0.09, 0.02)
MCPP n = 985 n = 971 n = 2,092
Q1
Q2 1.06 (–0.90, 3.02) 0.98 (–1.20, 3.15) 0.04 (–0.13, 0.20) 0.01 (–0.11, 0.13) –0.04 (–0.09, 0.00) –0.04 (–0.09, 0.00)
Q3 0.65 (–1.42, 2.73) 0.01 (–2.23, 2.24) 0.02 (–0.14, 0.17) –0.03 (–0.16, 0.10) –0.02 (–0.07, 0.03) –0.01 (–0.06, 0.04)
Q4 –0.06 (–2.24, 2.12) –0.49 (–3.01, 2.04) –0.07 (–0.23, 0.10) –0.01 (–0.15, 0.13) –0.06 (–0.12, –0.01) –0.07 (–0.12, –0.01)
MiBP n = 985 n = 971 n = 2,092
Q1
Q2 3.08 (1.22, 4.93) 3.03 (1.05, 5.00) 0.13 (–0.02, 0.28) 0.13 (0.01, 0.25) 0.03 (–0.01, 0.08) 0.03 (–0.01, 0.08)
Q3 3.50 (1.45, 5.54) 3.17 (1.17, 5.17) 0.08 (–0.08, 0.25) 0.10 (–0.01, 0.21) 0.03 (–0.02, 0.09) 0.04 (0.00, 0.09)
Q4 5.86 (3.55, 8.17) 6.04 (3.81, 8.28) 0.22 (0.06, 0.38) 0.18 (0.06, 0.31) 0.01 (–0.05, 0.07) 0.01 (–0.04, 0.07)
∑DEHP n = 976 n = 962 n = 2,074
Q1
Q2 0.35 (–1.50, 2.19) –0.13 (–2.08, 1.82) 0.12 (–0.04, 0.29) 0.01 (–0.11, 0.13) 0.04 (–0.01, 0.08) 0.02 (–0.02, 0.06)
Q3 –1.24 (–3.37, 0.89) –1.75 (–3.93, 0.44) 0.10 (–0.04, 0.24) 0.05 (–0.07, 0.16) –0.01 (–0.06, 0.04) –0.03 (–0.07, 0.02)
Q4 0.25 (–1.94, 2.44) 0.01 (–2.34, 2.36) 0.19 (0.02, 0.35) 0.13 (0.01, 0.25) 0.01 (–0.05, 0.07) –0.02 (–0.07, 0.03)
Q, quartile. For each of the phthalate categories, Q1 is the reference. 
aMedian regression used to conduct analysis. bAdjusted for urine creatinine, age, race/ethnicity, education, poverty status, fasting time, total caloric intake, total fat intake, smoking 
status, and physical activity. cAdjusted for urine creatinine, age, race/ethnicity, education, poverty status, fasting time, total caloric intake, total fat intake, smoking status, physical 
activity, BMI, and waist circumference.James-Todd et al.
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study, we cannot rule out the possibility of 
reverse causation. Phthalates are known to be 
in certain types of medications and medical 
devices, including medical products contain-
ing polyvinyl chloride used in intravenous 
bags and medical tubing. As such, it is pos-
sible that some of these associations are due 
to greater exposure to phthalates through 
increased use of certain medical devices and 
medications among women with diabe-
tes (Hauser et al. 2004; Kelley et al. 2012). 
Future studies should longitudinally evalu-
ate the association between phthalate levels 
and markers of insulin resistance and beta-cell 
functioning among nondiabetic women to 
better understand how phthalates could alter 
normal glucose metabolism and diabetes risk. 
Additionally, phthalate levels were measured 
using spot urines and do not account for 
temporal changes in exposure levels. Despite 
the rapid excretion of phthalates, which typi-
cally occurs within 24–48 hr (Hauser and 
Calafat 2005; Swan 2008) and vary within 
a person over time (Fromme et al. 2007), 
a number of studies show phthalate levels 
measured at one point to be modestly pre-
dictive of levels measured over the course of 
weeks or months (Hoppin et al. 2002; Peck 
et al 2010; Svensson et al. 2011). Although 
within-woman variability in phthalate levels 
is undoubtedly present, this type of measure-
ment error would likely lead to nondifferential 
misclassification and a bias toward the null. 
Future studies should examine multiple urine 
samples taken over time to better estimate 
long-term phthalate exposure.
We were also unable to assess combina-
tions of phthalates or adjust for exposure to 
different types of phthalates in this analysis. 
Exposure to a particular phthalate is unlikely 
to occur in isolation. Different phthalates 
may bind and activate different sets of genes, 
leading to potentially opposing effects on 
the normal functioning endocrine system. 
Correlation between phthalates and complex-
ity of their interaction make it difficult to 
assess potential combinations of phthalates 
and their impact on human health outcomes, 
including diabetes. Future studies may need 
to assess this association, as high levels of vari-
ous combinations of phthalates may increase 
the risk of diabetes.
Finally, type of diabetes was assessed by self-
report and did not distinguish between type 1 
and T2DM. Although we cannot differentiate 
diabetes type, we believe most (90–95%) of 
the persons had T2DM (Harris 1995). Also, 
self-reported diabetes may vary by education, 
age, and other factors. If more respondents of 
lower socioeconomic status inaccurately report 
not having diabetes, the resulting bias would 
be toward the null. Furthermore, a study using 
NHANES 2003–2006 reported that approxi-
mately 30% of diabetes cases were undiagnosed 
(Danaei et al. 2009), which could result in an 
under  estimate of the true association between 
phthalate exposure and diabetes.
Despite the limitations of this study, there 
are many strengths. First, we explored this 
research question in a large study population of 
women who participated in NHANES over an 
8-year period evaluating five individual phtha-
late metabolites and ∑DEHP metabolites. 
Second, our study population consisted of a 
representative sample of U.S. women. Third, 
we were able to control for several potential 
confounders, including sociodemographic, 
dietary, and behavioral factors. Fourth, to 
expand upon our findings of phthalates and 
prevalent diabetes, we conducted a secondary 
analysis among women without diagnosed 
diabetes. This analysis allowed us to explore 
the association between phthalates and mark-
ers of diabetes risk (FBG, HOMA-IR, and 
A1c). To our knowledge, this is the first study 
to examine the association between phthalates 
and diabetes in a large sample of women living 
in the United States.
In conclusion, urinary levels of MnBP, 
MiBP, MBzP, MCPP, and ∑DEHP were 
associated with diabetes among women. For 
women without diagnosed diabetes, some 
phthalate metabolites were positively associ-
ated with FBG and HOMA-IR. These find-
ings suggest the need to further explore the 
association between phthalates, insulin resis-
tance, and diabetes. If future studies determine 
causal links between phthalates and diabe-
tes, then reducing phthalate exposure could 
decrease the risk of diabetes among women.
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